We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Biochemistry
-
1. De novo designed proteins: a breakthrough in snakebite treatment
- Dr. Susana Vazquez Torres
- Cancer/Oncology
-
3. From lab to clinic: bridging cancer genetics and public health
- Prof. Clare Turnbull
-
4. Engineered yeast: a breakthrough in targeted cancer therapies
- Prof. Gautam Dantas
-
6. Cancer vaccines
- Dr. Elias Sayour
-
7. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
9. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
10. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Immunology & Inflammation
-
11. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
12. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
14. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
16. Kalihinol analog MED6-189: a promising pan-antimalarial candidate
- Prof. Karine Le Roch
-
17. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
19. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Methods
-
21. How big data and genomics are personalizing your health- Prof. Michael Snyder
-
22. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
23. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
24. MassBank development and future
- Dr. Emma L. Schymanski
-
25. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
26. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
- Neurology/Neuroscience
-
27. Duchenne muscular dystrophy: pathology, diagnostic strategies, and core molecular pathways- Prof. Steve Wilton
-
28. Rethinking the amyloid dogma in Alzheimer’s disease
- Prof. George Perry
-
29. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
30. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
31. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
32. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
33. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
34. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
35. Muscarinic acetylcholine receptor modulation in neurological diseases
- Prof. Andrew B. Tobin
- Pharmaceutical Sciences
-
36. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
37. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
39. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
40. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
41. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
42. The regulation of cell therapy
- Prof. Moutih Rafei
-
43. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
44. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
46. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
47. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
Topics Covered
- Antimalarial drug discovery
- Natural product analogues (Kalinol)
- Drug-resistant Plasmodium falciparum
- Mechanism of action studies
- Apicoplast targeting
- Vesicular trafficking pathways
- Semi-synthetic compound (MED6-189)
- Preclinical development and translational challenges
Biography
Professor Karine Le Roch is a Professor at the University of California, Riverside, whose research focuses on the molecular biology of malaria parasites. Her work explores gene regulation, epigenetics, and chromatin dynamics in Plasmodium falciparum, with the aim of understanding how the parasite progresses through its life cycle and evades host responses. Using advanced genomics and systems biology approaches, her research has contributed to identifying novel targets for antimalarial therapies.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Le Roch, K. (2026, May 28). Kalihinol analog MED6-189: a promising pan-antimalarial candidate [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 13, 2026, from https://doi.org/10.69645/RPFK4626.Export Citation (RIS)
Publication History
- Published on May 28, 2026
Financial Disclosures
- Prof. Karine Le Roch has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Microbiology
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: The research
group of Prof. Karine Le Roch
at the University of
California, Riverside,
recently published a
paper in Science Journal
detailing the synthesis of
an analog of kalihinol,
a sponge-derived
natural product,
which demonstrates activity
against drug-resistant malaria.
Prof. Roch has kindly
joined us today
to discuss her findings.
Prof. Roch, thank you very
much for joining us today.
Prof. Roch: Thank
you for having me.
Interviewer: Could you
provide some background
on the approach that you
took in this research
and what led you to focus
on kalihinol analogues?
Prof. Roch: So,
I've been working on
natural product
from drug discovery
against malaria for decades.
Over the years, my
work focused on
understanding not only
how the parasite can
survive inside a
human red blood cell,
but also how we can identify
new drugs and drug targets.
So we all know that successful
malaria chemotherapy
still have a strong historical
link to natural products
of which quinine
and artemisinin are
the two most important
antimalarial drugs
extracted from plants.
So why these natural products
are so successful drugs?
They offer a vast source of
chemically diverse compound with
potential therapeutic
properties,
they often exhibit a
unique molecular structure
that can lead to
novel drug candidates
with fewer side effects compared
to purely synthetic molecules,
and they are often very
relevant for tackling
complex disease and fight
mechanisms of drug resistance.
So as I said earlier,
malaria has a very strong
historical link to
natural products, and
I've been interested in
trying to discover new
products that could
actually be efficient
against malaria parasites.